Skip to main content
SpringerLink
Log in

Pembrolizumab cost effective as first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., NJ, USA.

Reference

  • Wurcel V, et al. Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina. Advances in Therapy : 15 Apr 2021. Available from: URL: http://doi.org/10.1007/s12325-021-01656-3

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pembrolizumab cost effective as first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma. PharmacoEcon Outcomes News 877, 15 (2021). https://doi.org/10.1007/s40274-021-7664-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-7664-5

Search

Navigation